Prepared for AstraZeneca

Together, delivering life-changing therapies at a scale your ambition demands

You’re scaling toward $80bn by 2030, tripling parenteral volume and bringing 20 new medicines to patients along the way.

As a world-class, integrated CDMO with more than five decades of experience and 90+ successful product launches a year, PCI Pharma Services is ready now to support your programs across vials, prefilled syringes, and autoinjector/pen devices with the expertise, science, and capacity to simplify the complex.

The volume is coming. We've been anticipating it.

Your global network strategy points to 104 upcoming programs, 60% of them on parenteral platforms. Vials are the single largest primary container format by count, with syringe and cartridge volumes rising as high-growth formats and cold chain demand expected to double. Stable and progressive, we’re always anticipating the future needs of our clients, and confirmed CMO capacity across the industry hasn’t kept pace with growth like this.

That’s precisely the gap PCI has spent the last several years closing with more than $1 billion invested in sterile fill-finish and drug-device combination infrastructure across the US and Europe, engineered for exactly the formats and volumes your pipeline demands. Rooted in experience, our industry-leading heritage engenders the trust to deliver the future legacy AstraZeneca is building.

$1,000,000,000 invested

Invested in sterile fill-finish & drug-device combination infrastructure

250 Million units per year

US device assembly capacity

400 units per minute

New isolator vial and lyophilization line capable of producing batch sizes of up to 300,000 vials at 400 units per minute

ESG-Aligned by Design

Our climate targets were approved by the Science-Based Targets initiative in 2025. We are committed to reducing scope 1 and 2 emissions by 47.7% from FY2023 base year by 2030, and scope 3 GHG emissions by 25% from FY2024 base year. By 2045 we are committed to reaching net-zero emissions across our entire value chain.

Our 2025 EcoVadis sustainability score of 70, a 12-point year-over year increase, reflects our progress and place us in the 83^rd percentile globally and the top 10% of our industry. This marks our fourth consecutive EcoVadis Bronze Medal and continued progress across all assessment themes.

Our Global ESG Program

The formats you need, at the scale you need them.

Whichever combination of vials, prefilled syringes, cartridges and autoinjector or pen devices your products require, PCI brings unparalleled knowledge, know-how, and expertise across our global integrated network with the flexibility to shift format mix as your programs evolve from clinical to commercial scale.

Vials

High-speed, and lyophilized; engineered at true commercial scale.

Isolator-based aseptic filling up to 400 vials per minute, batch sizes up to 300,000 units, with Annex 1-compliant containment across our newest facilities
World-class expertise in the science of lyophilization, with twin 40m2 lyophilizers and automated loading/unloading for complex biologics
Comprehensive clinical and commercial vial packaging and labelling expertise managing light and oxygen-sensitive products, temperature-controlled cold chain and low-humidity environments with precision.

Prefilled Syringes

From 2,000 to 300,000 syringes per batch

Specialist capabilities including high-volume prefilled syringe filling, scaling from low/mid volume through high-volume production under one roof.
Multi-platform technology supporting complex biologics, peptides, and small molecules in ready-to-use syringe formats
An integrated path from sterile fill straight into device assembly, package design, and testing coordinated across our integrated network
Adding 60M units per year in prefilled syringe/cartridge capacity in the US & EU

Autoinjectors & Pen Devices

Device-agnostic assembly, engineered for the formats you use today and the ones you'll need tomorrow.

Isolator-based cartridge filling across our US and EU network, for an integrated fill-to-device pathway with no third-party handoff
Multi-platform technology with rapid changeover across the majority of current formats
Expanding device assembly capacity toward 250M+ units per year
Extensive cold chain capabilities to support drug-device combination products, backed by in-house performance testing and human factor studies
Lifecycle Assessments and Sustainable package design to reduce environmental impact.

Invested where it matters most. Capacity, quality and reach.

Our teams can support AstraZeneca with world-class CDMO solutions from development through commercialization and beyond with quality and safety built into every step of the product pathway. As a premium CDMO, we hold ourselves to the highest standards, and we’ve made significant, sustained investments to strengthen delivery, quality, and reach across our integrated network. AstraZeneca’s strategy calls for regional manufacturing and packaging capability in both the EU and US for every launch. PCI’s network is built exactly that way, with free trade zone capabilities and supply chain expertise that give your products regionally secure supply without sacrificing a single, unified quality standard.

Automated visual inspection at scale

New AVI systems will support more than 70 million prefilled syringes and cartridges, and 40 million vials, annually.

Deeper device expertise

Significant new investment in autoinjector and pen device assembly infrastructure, backed by device-agnostic tooling that adapts as technology evolves

Supply chain resilience

Foreign trade zone and customs warehousing support, plus Pre-IND program experience, from our experts in tariff mitigation

Global reach, local execution

Sterile fill-finish and device assembly footprints across North America and Europe, positioned where your launches need them

From concept to launch: how we bring your product to life

A full team on your side: every program is supported by a cross-functional team of segment project managers, quality specialists, and engineers - giving you direct, hands-on access to the experts driving your project at every site.

Governed for alignment: that team is overseen by a dedicated Integrated Program Manager (iPM), who governs coordination, timelines, and visibility across our Commercial, Clinical, and Development & Manufacturing segments.

We learn your product, requirements, and goals through a structured kickoff, aligning your team and ours around a shared plan. Here, you’ll meet your iPM.

We define the equipment, resources, quality requirements, and timeline needed to bring your product onto our site.

Our teams design and commission the process, schedule production, and prepare the batch records and test methods it depends on.

Every process, method, and system is qualified and validated to GxP standards, with full documentation ready for regulatory review.

We hand over a validated, audit-ready process and stay engaged through regular tracking calls and continuous monitoring. Your iPM stays engaged, every step of the way.